Cassava Sciences Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cassava Sciences stock.
View analyst ratings for Cassava Sciences or view top-rated stocks.

Wall Street analysts have given Cassava Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cassava Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Cassava Sciences.

Cassava Sciences, Inc. (NASDAQ:SAVA) announced its quarterly earnings data on Tuesday, April, 20th. The company reported ($0.09) EPS for the quarter, beating the Zacks' consensus estimate of ($0.10) by $0.01.
View Cassava Sciences' earnings history.

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAVA shares have increased by 1,539.9% and is now trading at $69.53.
View which stocks have been most impacted by COVID-19.

Cassava Sciences shares reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

5 equities research analysts have issued twelve-month price objectives for Cassava Sciences' shares. Their forecasts range from $14.00 to $124.00. On average, they anticipate Cassava Sciences' share price to reach $87.25 in the next year. This suggests a possible upside of 25.5% from the stock's current price.
View analysts' price targets for Cassava Sciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Cassava Sciences include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Dr. Reddy's Laboratories (RDY), Grifols (GRFS), Jazz Pharmaceuticals (JAZZ), CureVac (CVAC), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Perrigo (PRGO) and Ascendis Pharma A/S (ASND).
View all of SAVA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Cassava Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%), Alliancebernstein L.P. (0.11%), IVC Wealth Advisors LLC (0.02%), Golden Green Inc. (0.02%), Investors Financial Group LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Cassava Sciences stock include Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends for Cassava Sciences.

SAVA stock was sold by a variety of institutional investors in the last quarter, including Investors Financial Group LLC.
View insider buying and selling activity for Cassava Sciences or view top insider-selling stocks.

SAVA stock was acquired by a variety of institutional investors in the last quarter, including Cutler Group LP, Alliancebernstein L.P., Zurcher Kantonalbank Zurich Cantonalbank , IVC Wealth Advisors LLC, and Golden Green Inc.. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson.
View insider buying and selling activity for Cassava Sciences or or view top insider-buying stocks.

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAVA stock can currently be purchased for approximately $69.53.

Cassava Sciences has a market capitalization of $2.78 billion. The company earns $-6,330,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

Cassava Sciences employs 11 workers across the globe.

The official website for Cassava Sciences is www.cassavasciences.com.

Cassava Sciences is headquartered at 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731.

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]